

Read in open court this 25th day of
February, 2019.

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

AMGEN INC.; AMGEN MANUFACTURING,)
LIMITED; and AMGEN USA INC.)

Plaintiffs,)

v.)

SANOFI; SANOFI-AVENTIS U.S. LLC;)
AVENTISUB LLC, f/d/b/a AVENTIS)
PHARMACEUTICALS INC., and REGENERON)
PHARMACEUTICALS, INC.,)

Defendants.)

C.A. No.: 14-1317-RGA
(CONSOLIDATED)

VERDICT

In the following questions, "Amgen" refers to plaintiffs Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA Inc., and "Sanofi-Regeneron" refers to defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC, f/d/b/a Aventis Pharmaceuticals Inc., and Regeneron Pharmaceuticals, Inc.

VALIDITY

1. The '165 patent

a. Has Sanofi-Regeneron proven by clear and convincing evidence that the following claims of the '165 patent are invalid because the patent does not enable a person of ordinary skill in the art to make or use the invention of the following claims of the '165 patent?

Checking "yes" below indicates a finding for Sanofi-Regeneron.

Checking "no" below indicates a finding for Amgen.

| | | |
|----------|---------|--|
| Claim 7 | Yes ___ | No <input checked="" type="checkbox"/> |
| Claim 15 | Yes ___ | No <input checked="" type="checkbox"/> |
| Claim 19 | Yes ___ | No <input checked="" type="checkbox"/> |
| Claim 29 | Yes ___ | No <input checked="" type="checkbox"/> |

b. Has Sanofi-Regeneron proven by clear and convincing evidence that the following claims of the '165 patent are invalid because the patent lacks adequate written description?

Checking "yes" below indicates a finding for Sanofi-Regeneron.

Checking "no" below indicates a finding for Amgen.

| | | |
|----------|---|--|
| Claim 7 | Yes <input checked="" type="checkbox"/> | No ___ |
| Claim 15 | Yes <input checked="" type="checkbox"/> | No ___ |
| Claim 19 | Yes ___ | No <input checked="" type="checkbox"/> |
| Claim 29 | Yes ___ | No <input checked="" type="checkbox"/> |

Continue to next page.

2. The '741 patent

a. Has Sanofi-Regeneron proven by clear and convincing evidence that claim 7 of the '741 patent is invalid because the patent does not enable a person of ordinary skill in the art to make or use the invention in claim 7 of the '741 patent?

Checking "yes" below indicates a finding for Sanofi-Regeneron.

Checking "no" below indicates a finding for Amgen.

Claim 7 Yes _____ No

b. Has Sanofi-Regeneron proven by clear and convincing evidence that claim 7 of the '741 patent is invalid because the patent lacks adequate written description?

Checking "yes" below indicates a finding for Sanofi-Regeneron.

Checking "no" below indicates a finding for Amgen.

Claim 7 Yes _____ No

Continue to next page.

We, the jurors, by signing below, indicate our unanimous verdict.



Juror




Juror



Juror



Juror



Juror



Juror



Juror

Dated: 8/25/19